Tocilizumab is effective against polymyalgia rheumatica

Experience in 13 intractable cases

Keisuke Izumi, Harumi Kuda, Mari Ushikubo, Masataka Kuwana, Tsutomu Takeuchi, Hisaji Oshima

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are effective in treating PMR, they frequently result in side effects. Therefore, we conducted a retrospective study to assess the effectiveness and safety of tocilizumab as an alternative to glucocorticoids. We included 13 consecutive patients with PMR (11 women and 2 men; median age, 74 years) diagnosed according to Bird's criteria and the 2012 European League Against Rheumatism/ American College of Rheumatology provisional classification criteria. All patients received tocilizumab infusion (8 mg/kg every 4 weeks) at our institutions, between 2008 and 2014, because of PMR relapses (n=12) or insufficient response to initial prednisolone treatment (n=1), without increasing prednisolone dosage. Seven patients were on methotrexate, and all had one or more glucocorticoid-related comorbidities. Administration of tocilizumab significantly improved inflammation and PMR symptoms such as morning stiffness, as well as the Patient-Pain and Patient-Global Assessment visual analogue scales ( p<0.05). Proximal muscle pain disappeared within 8 weeks, on average, and the Health Assessment Questionnaire-Disability Index scores (p=0.098) and concomitant prednisolone doses (p<0.05) decreased at 12 weeks. Severe adverse events were not observed during the mean tocilizumab treatment period of 43.4 weeks. Our findings suggest that tocilizumab is effective and safe for PMR treatment.

Original languageEnglish
Article numbere000162
JournalRMD Open
Volume1
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Polymyalgia Rheumatica
Prednisolone
Glucocorticoids
Myalgia
Visual Analog Scale
Methotrexate
Birds
tocilizumab
Comorbidity
Therapeutics
Retrospective Studies
Inflammation
Safety
Recurrence
Pain
Health

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Tocilizumab is effective against polymyalgia rheumatica : Experience in 13 intractable cases. / Izumi, Keisuke; Kuda, Harumi; Ushikubo, Mari; Kuwana, Masataka; Takeuchi, Tsutomu; Oshima, Hisaji.

In: RMD Open, Vol. 1, No. 1, e000162, 01.01.2015.

Research output: Contribution to journalArticle

Izumi, Keisuke ; Kuda, Harumi ; Ushikubo, Mari ; Kuwana, Masataka ; Takeuchi, Tsutomu ; Oshima, Hisaji. / Tocilizumab is effective against polymyalgia rheumatica : Experience in 13 intractable cases. In: RMD Open. 2015 ; Vol. 1, No. 1.
@article{daa73fbe25d94541b13e57f9b88953ce,
title = "Tocilizumab is effective against polymyalgia rheumatica: Experience in 13 intractable cases",
abstract = "Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are effective in treating PMR, they frequently result in side effects. Therefore, we conducted a retrospective study to assess the effectiveness and safety of tocilizumab as an alternative to glucocorticoids. We included 13 consecutive patients with PMR (11 women and 2 men; median age, 74 years) diagnosed according to Bird's criteria and the 2012 European League Against Rheumatism/ American College of Rheumatology provisional classification criteria. All patients received tocilizumab infusion (8 mg/kg every 4 weeks) at our institutions, between 2008 and 2014, because of PMR relapses (n=12) or insufficient response to initial prednisolone treatment (n=1), without increasing prednisolone dosage. Seven patients were on methotrexate, and all had one or more glucocorticoid-related comorbidities. Administration of tocilizumab significantly improved inflammation and PMR symptoms such as morning stiffness, as well as the Patient-Pain and Patient-Global Assessment visual analogue scales ( p<0.05). Proximal muscle pain disappeared within 8 weeks, on average, and the Health Assessment Questionnaire-Disability Index scores (p=0.098) and concomitant prednisolone doses (p<0.05) decreased at 12 weeks. Severe adverse events were not observed during the mean tocilizumab treatment period of 43.4 weeks. Our findings suggest that tocilizumab is effective and safe for PMR treatment.",
author = "Keisuke Izumi and Harumi Kuda and Mari Ushikubo and Masataka Kuwana and Tsutomu Takeuchi and Hisaji Oshima",
year = "2015",
month = "1",
day = "1",
doi = "10.1136/rmdopen-2015-000162",
language = "English",
volume = "1",
journal = "RMD Open",
issn = "2056-5933",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Tocilizumab is effective against polymyalgia rheumatica

T2 - Experience in 13 intractable cases

AU - Izumi, Keisuke

AU - Kuda, Harumi

AU - Ushikubo, Mari

AU - Kuwana, Masataka

AU - Takeuchi, Tsutomu

AU - Oshima, Hisaji

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are effective in treating PMR, they frequently result in side effects. Therefore, we conducted a retrospective study to assess the effectiveness and safety of tocilizumab as an alternative to glucocorticoids. We included 13 consecutive patients with PMR (11 women and 2 men; median age, 74 years) diagnosed according to Bird's criteria and the 2012 European League Against Rheumatism/ American College of Rheumatology provisional classification criteria. All patients received tocilizumab infusion (8 mg/kg every 4 weeks) at our institutions, between 2008 and 2014, because of PMR relapses (n=12) or insufficient response to initial prednisolone treatment (n=1), without increasing prednisolone dosage. Seven patients were on methotrexate, and all had one or more glucocorticoid-related comorbidities. Administration of tocilizumab significantly improved inflammation and PMR symptoms such as morning stiffness, as well as the Patient-Pain and Patient-Global Assessment visual analogue scales ( p<0.05). Proximal muscle pain disappeared within 8 weeks, on average, and the Health Assessment Questionnaire-Disability Index scores (p=0.098) and concomitant prednisolone doses (p<0.05) decreased at 12 weeks. Severe adverse events were not observed during the mean tocilizumab treatment period of 43.4 weeks. Our findings suggest that tocilizumab is effective and safe for PMR treatment.

AB - Polymyalgia rheumatica (PMR) affects older people, and although glucocorticoids are effective in treating PMR, they frequently result in side effects. Therefore, we conducted a retrospective study to assess the effectiveness and safety of tocilizumab as an alternative to glucocorticoids. We included 13 consecutive patients with PMR (11 women and 2 men; median age, 74 years) diagnosed according to Bird's criteria and the 2012 European League Against Rheumatism/ American College of Rheumatology provisional classification criteria. All patients received tocilizumab infusion (8 mg/kg every 4 weeks) at our institutions, between 2008 and 2014, because of PMR relapses (n=12) or insufficient response to initial prednisolone treatment (n=1), without increasing prednisolone dosage. Seven patients were on methotrexate, and all had one or more glucocorticoid-related comorbidities. Administration of tocilizumab significantly improved inflammation and PMR symptoms such as morning stiffness, as well as the Patient-Pain and Patient-Global Assessment visual analogue scales ( p<0.05). Proximal muscle pain disappeared within 8 weeks, on average, and the Health Assessment Questionnaire-Disability Index scores (p=0.098) and concomitant prednisolone doses (p<0.05) decreased at 12 weeks. Severe adverse events were not observed during the mean tocilizumab treatment period of 43.4 weeks. Our findings suggest that tocilizumab is effective and safe for PMR treatment.

UR - http://www.scopus.com/inward/record.url?scp=85018192728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018192728&partnerID=8YFLogxK

U2 - 10.1136/rmdopen-2015-000162

DO - 10.1136/rmdopen-2015-000162

M3 - Article

VL - 1

JO - RMD Open

JF - RMD Open

SN - 2056-5933

IS - 1

M1 - e000162

ER -